Rovalpituzumab Tesirine (DLL3 antibody-drug conjugate) for IDH1-mutant glioma - Hallo friendsTOP POLENNEWS, In the article you read this time with the title Rovalpituzumab Tesirine (DLL3 antibody-drug conjugate) for IDH1-mutant glioma, We have prepared this article for you to read and retrieve information therein. Hopefully the contents of postings Article cultur, Article economic, Article health, Article news, Article politique, Article sport, We write this you can understand. Alright, good read.

Title : Rovalpituzumab Tesirine (DLL3 antibody-drug conjugate) for IDH1-mutant glioma
link : Rovalpituzumab Tesirine (DLL3 antibody-drug conjugate) for IDH1-mutant glioma

Rovalpituzumab Tesirine (DLL3 antibody-drug conjugate) for IDH1-mutant glioma

Cell surface Notch ligand DLL3 is a therapeutic target in isocitrate dehydrogenase mutant glioma

pubmed link

full article download

"DLL3 immunostaining was intense and homogeneous in IDH mutant gliomas, retained in all recurrent tumors, and detected in only 1 of 20 non-tumor brains. Patient-derived IDH mutant glioma tumorspheres overexpressed DLL3 and were potently sensitive to Rova-T in an antigen-dependent manner."

This is particularly interesting because the therapy is currently available in a clinical trial for recurrent GBM and other solid tumors recruiting at multiple locations across the USA.

https://clinicaltrials.gov/ct2/show/study/NCT02709889?show_locs=Y#locn

Thus Article Rovalpituzumab Tesirine (DLL3 antibody-drug conjugate) for IDH1-mutant glioma

That's an article Rovalpituzumab Tesirine (DLL3 antibody-drug conjugate) for IDH1-mutant glioma This time, hopefully can give benefits to all of you. well, see you in posting other articles.

You are now reading the article Rovalpituzumab Tesirine (DLL3 antibody-drug conjugate) for IDH1-mutant glioma with the link address https://polennews.blogspot.com/2018/11/rovalpituzumab-tesirine-dll3-antibody.html

Tweet

Subscribe to receive free email updates: